ImmuneWalk Therapeutics
United States
- Pearl River, New York
- 08/05/2025
- Seed
- $7,000,000
ImmuneWalk Therapeutics is a private clinical-stage company focused on development of novel therapies for chronic inflammatory diseases. Our Monocyte Targeting Technology (MTT) is designed to selectively block the migration (`walking`) of monocytes from the blood stream into inflamed tissues. Our lead candidate, IW-601, is a proprietary monoclonal antibody that is engineered to specifically prevent monocytes from exiting the blood stream and traveling to inflammatory sites. IW-601 is designed to offer a novel and differentiated approach in the landscape of current anti-inflammatory agents.
With clear disease-modifying activity in models of Multiple Sclerosis, Rheumatoid Arthritis, Inflammatory Bowel Disease and Non- Alcoholic Steatohepatitis, in addition to proof-of-concept from patient’s cells, we are advancing IW-601 to a Ph1 clinical trial.
- Industry Biotechnology Research
- Website https://immunewalk.com/
- LinkedIn https://www.linkedin.com/company/immunewalk-therapeutics/
Vector 👻 | $10,000,000 | (May 14, 2026)
Avant Genomics | $3,000,000 | (May 14, 2026)
Data Mission | $1,000,000 | (May 14, 2026)
SwishX | $2,200,000 | (May 14, 2026)
Dolfin | $2,460,580 | (May 14, 2026)
4AM | $4,000,000 | (May 13, 2026)
Sedivention - Freezing the hunger feeling | $3,402,541 | (May 13, 2026)
Meatly | $14,074,996 | (May 13, 2026)
NanoStruct GmbH | $3,050,853 | (May 13, 2026)
Adfin | $18,000,000 | (May 13, 2026)
Boundary | $2,000,000 | (May 13, 2026)
Knit Health | $11,600,000 | (May 13, 2026)